⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BCTXL News
BriaCell Therapeutics Corp. Warrant expiring 2031
BriaCell Announces Six Clinical Data Presentations at ASCO 2026
globenewswire.com
BCTX
BCTXW
BCTXZ
BCTXL
BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models
globenewswire.com
BCTX
BCTXW
BCTXZ
BCTXL
BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting
globenewswire.com
BCTX
BCTXW
BCTXZ
BCTXL
Form 8-K
sec.gov
BCTX
BCTXL
BCTXZ
BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License
globenewswire.com
BCTX
BCTXW
BCTXZ
BCTXL
BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference
globenewswire.com
BCTX
BCTXW
BCTXZ
BCTXL
Form 8-K
sec.gov
BCTXZ
BCTX
BCTXL
BCTXW
Form 8-K
sec.gov
BCTXL
BCTXZ
BCTXW
BCTX
BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License
globenewswire.com
BCTX
BCTXW
BCTXZ
BCTXL
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
globenewswire.com
BCTX
BCTXW
BCTXZ
BCTXL